Evan Seigerman

what you think needs to change from a policy perspective to encourage even more uptake of biosimilars.

I'm really trying to understand kind of what's driving the volume. Is it increased penetration into that refractory population?

with the Q code in place, can you help us think about the near-term uptake of PAVBLU in the field?

Can you walk me through some of the drivers of this

Should we think about what that could do to your top line growth for 2026 in the rare disease business

how this renewed focus can drive growth and pipeline expansion into the end of the decade

how that potential for at-home administration can help accelerate sales in the United States

I want to touch very briefly on the use of GLP-1s in Alzheimer’s disease. Novo Nordisk has talked a lot about the EVOKE trial

Can you walk me through the aspects of the trial design, patient selection that increased your confidence

Can you just help frame how that maybe informs how you're thinking about your partnership with BioNTech

What attracts you to the partnership with them? Maybe walk me through some of the differentiation

the potential impact positive impact on relaxed cardiac monitoring for Camzyos and how this could help accelerate sales

the potential implementation of most favored nation's pricing potentially, with regard to drug price negotiation in the IRA

What are you seeing in the field that's driving the uptake there

can you walk us through kind of your process in determining why you went for Karuna

Can you just talk to me about the level of appetite for additional BD and liver-focused indications such as NASH

If PrEP is removed as a preventative medicine broadly, how does this change your approach to commercialization

Are you seeing more share or competitive share capture from competitive cell therapy products or bispecifics

talk to me about how you plan to manage the placebo response to this trial, especially with it being tested in kind of the mild to moderate patient population

can you walk me through how the current pipeline needs to mature to drive growth to the Jakafi LOE

can you remind us how you're thinking about sort of the peak opportunity for this product? And kind of has the launch trajectory in the early days change that

you noted a slight reduction in inventory, which maybe dampened sales. Could you quantify the impact any further?

Just walk me through some of the initial assumptions for the pediatric Opzelura launch. What does this initial uptake curve look like

what do you need to see from either the I&I, neuroscience or oncology franchises to kind of match the scale

A year from now on this call, I'd love for you to characterize what you would ask for a good product launch

could you expand on what drives this view and how it has changed since the initiation of the program

can you provide some practical examples of what you and the industry can do to help achieve the goals of getting price parity globally?

Can you provide some additional detail on what FDA wants to see in regard to additional data and what you didn't have from the SUMMIT trial

contextualize the importance of a dual regimen versus the standard of care of bictegravir Biktarvy

can you just talk about the initial feedback, say, versus the competition

I'd love if you could expand on your approach to diligencing assets between Chinese and Western companies

what else do you need to see to potentially start buying back shares, especially at these levels?

How what are some metrics you're putting around that? And more broadly, I just want to ensure that this is going to derive a good return

Assuming Metsera closes, what near-term factors must you consider to continue growing the dividend and then delevering

what do you believe are the 2 or 3 assets that have the potential to really drive a positive IRR for the $42 billion or so that you spent?

What are some key aspects of the profile that you're looking for either from an internal perspective or potentially externally?

can you walk me through how you plan on working with him as a likely head of HHS, especially with his views on vaccines

walk me through the commercial considerations for developing your combo GLP-1/GIP plus Praluent

what's differentiated about this asset from currently available standard of care and other advanced assets

can you walk me through some of the internal changes you've made with your regulatory manufacturing teams

with some of your key products marketed outside of the United States by partners, specifically European partners

if you could redesign a way to provide patient assistance without the use of charities

I want to expand a little bit on the discontinuation of VX-522. Anything else you can share on the tolerability issues?

Just seems to be a more crowded rare disease. I would love for you to just touch on differentiates this asset

Can you put the context of how important this is maybe in relationship to other competitive products that could be on the market

Can you kind of walk me through the rationale for prioritizing indications such as gMG, warm autoimmune hemolytic anemia

what are some of the key hurdles that are accelerated -- that are kind of preventing the acceleration of the uptake

Talk to me a little bit about how your early discussions with payers have been progressing